Market News AIOpen the app

Prelude Therapeutics says the FDA has approved its first study for a new breast cancer drug.

TrialRead the original at sec.gov
Good for PRLD

Prelude received FDA clearance to begin a Phase 1 study of PRT13722 for HR+ breast cancer. That advances its clinical program and may create future data catalysts.

PRLD · Prelude Therapeutics Inc

AI read · Good for PRLD

The AI's read

Prelude said the FDA cleared its IND to start a Phase 1 study of PRT13722. This moves the drug into human testing and creates a path to clinical data.

Get alerts for PRLD

Follow Prelude Therapeutics Inc (PRLD) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for PRLD
Free on the App Store and Google Play, or on the web.